Validation of prognostic factors in malignant pleural mesothelioma: A retrospective analysis of data from patients seeking compensation from the New South Wales dust diseases board

Clinical Lung Cancer

Volumn 14, Issue 1, 2013, Pages 70-77

  Kao, Steven C ^a,b,c   Vardy, Janette ^b,c   Chatfield, Mark ^c   Corte, Peter ^d   Pavlakis, Nick ^c,e   Clarke, Christopher ^a   Van Zandwijk, Nico ^a,c   Clarke, Stephen ^c,e  

^a Asbestos Diseases Research Institute   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Histologic subtype; Neutrophil to lymphocyte ratio; Stage; Systemic inflammation

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE SEVERITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PREDICTIVE VALUE; RETROSPECTIVE STUDY; THROMBOCYTE COUNT;

AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; HEMOGLOBINS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MESOTHELIOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEUTROPHILS; NEW SOUTH WALES; PLATELET COUNT; PLEURAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84871586459     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.03.011     Document Type: Article

References (34)

1. N.J. Vogelzang, J.J. Rusthoven, J. Symanowski Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644
2. E. Tracey, T. Kerr, A. Dobrovic Cancer in NSW: Incidence and Mortality Report 2008 2010 Cancer Institute NSW Sydney
3. D. Curran, T. Sahmoud, P. Therasse Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience J Clin Oncol 16 1998 145 152
4. J.E. Herndon, M.R. Green, A.P. Chahinian Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and Leukemia Group B Chest 113 1998 723 731
5. J.P. van Meerbeeck, R. Gaafar, C. Manegold Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer lung cancer group and the National Cancer Institute of Canada J Clin Oncol 23 2005 6881 6889
6. J. Symanowski, J. Rusthoven, B. Nguyen Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed + cisplatin vs. cisplatin in malignant pleural mesothelioma Proc Am Soc Clin Oncol 22 2003 abstract 2602
7. F. Pagès, A. Berger, M. Camus Effector memory T cells, early metastasis, and survival in colorectal cancer N Engl J Med 353 2005 2654 2666
8. L. Zhang, J.R. Conejo-Garcia, D. Katsaros Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 348 2003 203 213
9. K.I. Al-Shibli, T. Donnem, S. Al-Saad Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer Clin Cancer Res 14 2008 5220 5227
10. D.C. McMillan, J.E. Crozier, K. Canna Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer Int J Colorectal Dis 22 2007 881 886
11. K.M. Sarraf, E. Belcher, F. Raevsky Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer J Thorac Cardiovasc Surg 137 2009 425 428
12. A.K. Nowak, M.R. Stockler, M.J. Byrne Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer core quality of life questionnaire and lung cancer module J Clin Oncol 22 2004 3172 3180
13. B.W. Robinson, A.W. Musk, R.A. Lake Malignant mesothelioma Lancet 366 2005 397 408
14. S.C. Kao, N. Pavlakis, R. Harvie High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy Clin Cancer Res 16 2010 5805 5813
15. S.C. Kao, S. Klebe, D.W. Henderson Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy J Thorac Oncol 6 2011 1923 1929
16. S. Kao, N. van Zandwijk, S. Clarke The pattern of care for malignant pleural mesothelioma (MPM) patients compensated by the NSW Dust Diseases Board Respirology 16 2011 64 (abstract TP-108)
17. A. Bottomley, C. Coens, F. Efficace Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma J Clin Oncol 25 2007 5770 5776
18. D. Page, I. Fleming, A. Fritz AJCC Cancer Staging Manual 6th ed. 2002 Springer New York
19. R. Spirtas, R.R. Connelly, M.A. Tucker Survival patterns for malignant mesothelioma: the SEER experience Int J Cancer 41 1988 525 530
20. J.G. Edwards, K.R. Abrams, J.N. Leverment Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems Thorax 55 2000 731 735
21. K. Antman, R. Shemin, L. Ryan Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985 J Clin Oncol 6 1988 147 153
22. C. Boutin, F. Rey, J. Gouvernet Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients Part 2: prognosis and staging Cancer 72 1993 394 404
23. V. de Pangher Manzini, A. Brollo, S. Franceschi Prognsotic factors of malignant mesothelioma of the pleura Cancer 72 1993 410 417
24. A. Calavrezos, G. Koschel, H. Hüsselmann Malignant mesothelioma of the pleura A prospective therapeutic study of 132 patients from 1981-1985 Klin Wochenschr 66 1988 607 613
25. T. van Gelder, R.A. Damhuis, H.C. Hoogsteden Prognostic factors and survival in malignant pleural mesothelioma Eur Respir J 7 1994 1035 1038
26. L. Tammilehto Malignant mesothelioma: prognostic factors in a prospective study of 98 patients Lung Cancer 8 1992 175 184
27. C. Boutin, F. Rey Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients Part 1: diagnosis Cancer 72 1993 389 393
28. A. Nakas, E. Black, J. Entwisle Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage? Eur J Cardiothorac Surg 37 2010 1457 1463
29. D.J. Pinato, F.A. Mauri, R. Ramakrishnan Inflammation-based prognostic indices in malignant pleural mesothelioma J Thorac Oncol 7 2012 587 594
30. A.C. Tanrikulu, A. Abakay, M.A. Kaplan A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma Respiration 80 2010 480 487
31. B.M. Burt, S.J. Rodig, T.R. Tilleman Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma Cancer 117 2011 5234 5244
32. K. Suzuki, K. Kadota, C.S. Sima Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients Cancer Immunol Immunother 60 2011 1721 1728
33. J.P. Hegmans, A. Hemmes, H. Hammad Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses Eur Respir J 27 2006 1086 1095
34. Safe Work Australia Mesothelioma in Australia: Incidence 1982 to 2007; Mortality 1997-2007 2011 Commonwealth of Australia Canberra